New hope for Tough-to-Treat throat cancer patients

NCT ID NCT07496190

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called becotatug vedotin for people with advanced nasopharyngeal cancer (a type of throat cancer) who don't respond well to the standard first treatment of chemotherapy plus immunotherapy. The goal is to see if adding this new drug during radiation and follow-up treatment can help patients live longer without their cancer getting worse. The trial will enroll about 59 patients to measure survival rates and track side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NASOPHARYNGEAL CANCINOMA (NPC)